Getting itchy dogs back to normal
Zenrelia™ gets nearly 50% more itchy dogs back to normal than Apoquel®1††
A higher proportion of dogs treated with Zenrelia achieved a PVAS (Pruritis Visual Analogue Scale) score of less than two by day 112, compared to dogs treated with Apoquel. A 'normal' itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.
Veterinary experts rate Zenrelia
“So we have a medication that is once a day right from the start. I think it will really help improve that owner, patient, pet bond, it will hopefully help reduce caregiver burden and will improve patient and carer quality of life as well. Knowing what I currently know about Zenrelia, then I would be keen to use it in the clinic and start prescribing it.”
Dr Victoria Robinson BVM&S, BSc, CertAVP (VD), DipECVD, MRCVS
RCVS and European Specialist in Veterinary Dermatology
Zenrelia offers significant improvement in skin lesions vs. Apoquel from day 281†††
The Canine Atopic Dermatitis Extent & Severity Index (CADESI) is a tool to help measure the level of skin lesions in dogs, used widely in clinical studies.4
Vet-assessed skin lesion score (CADESI-04)
Study Design and Key Inclusion/Exclusion Criteria1
How Zenrelia works
Zenrelia is the only JAK inhibitor with high potency for JAK1, JAK2 & TYK2, key JAK enzymes involved in itch and inflammation¥, 5-7. By targeting multiple JAK enzymes & inhibiting the function of several cytokines involved in itch and inflammation, Zenrelia gets more itchy dogs back to normal than Apoquel, with a comparable safety profileα**1,5,6,8,9.
The best way to evaluate a JAK inhibitor efficacy and safety is through head to head real-world studies9,10. JAK selectivity based on in vitro assays shouldn't be used in isolation to evaluate product efficacy and safety10.
Questions?
Zenrelia Resources
* Referenceable claims in digital & social copy can be found on this page. Full reference list below.
** 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1.
BID, twice-daily; IRTT, investigator-assessed response to treatment; ORTT, owner-assessed response to treatment; SID, once daily; VAS, visual analogue scale.
†Response to treatment was assessed using a simple VAS scale graded from 'no improvement' at 0 cm to 'excellent improvement' at 10 cm1.
††A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.
†††Improvement based on mean CADESI-04 scores from Day 28. A CADESI-04 score of <10 is comparable to that of a healthy, non-allergic dog1.
‡ 79% of owners expect a PVAS of 0-1.92.
¥ Multiple JAK enzymes are involved in itch and inflammation, in particular JAK1,JAK2 & TYK211.
α Proinflammatory & pruritogenic cytokines implicated in allergic skin disease & allergic responses include IL-2, IL-6, IL-4,, IL-13 & IL-316.
- Forster S et al. Vet Dermatol 2025 Apr,36(2):165-176.
- Rybnícek J. et al. Vet Dermatol 2009;20(2):115–122.
- Hill P. B. et al. Vet Dermatol 2007;18(5):301–308.
- Olivry T et al. Vet Dermatol. 2014 Apr;25(2):77–85, e25.Schwartz DM et al.
- Unpublished data: JAK selectivity profile report.
- Gonzalez AJ et al. J. vet. Pharmacol. Therap. 37, 317--324.
- Howell MD, Kuo FI and Smith PA. Front. Immunol 2019;10:2342. doi: 10.3389/fimmu.2019.02342.
- Zenrelia Summary of Product Characteristics.
- Virtanen A, et al. Arthritis & Rheumatology. 2023 Nov;75(11):2054-61.
- Bonelli M, et al. Ann Rheum Dis 2024;83:139-160.
- Lin CM, Cooles FA, Isaacs JD. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):100-104.
